The protective effect of melatonin on brain ischemia and reperfusion in rats and humans: In vivo assessment and a randomized controlled trial.
Study Goal
The researchers aimed to investigate the neuroprotective effects of melatonin on ischemia and reperfusion (I/R) injury in rats and humans following carotid endarterectomy (CEA).
Results Summary
Melatonin reduced inflammatory markers (NF-κB, IL-6, S100β) and increased antioxidant activity (Nrf2, SOD, CAT, GPx) in both rats and humans, suggesting it ameliorates brain I/R injury through antioxidant and anti-inflammatory effects.
Population
Male rats and human patients undergoing CEA.
Effective Dosage
6 mg/d orally in humans.
Duration
From 3 days before surgery to 3 days after surgery (total 6 days).
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
melatonin | decrease | nuclear factor κ light-chain-enhancer of activated B cells (NF-κB) | rats | P < 0.05 | decreased the expression | #1 |
melatonin | decrease | S100 calcium-binding protein β (S100β) | rats | P < 0.05 | decreased the expression | #2 |
melatonin | increase | nuclear erythroid 2-related factor 2 (Nrf2) | rats | P < 0.05 | markedly increased the expression | #3 |
melatonin | increase | superoxide dismutase (SOD) | rats | P < 0.05 | markedly increased the expression | #4 |
melatonin | increase | catalase (CAT) | rats | P < 0.05 | markedly increased the expression | #5 |
melatonin | increase | glutathione peroxidase (GPx) | rats | P < 0.05 | markedly increased the expression | #6 |
melatonin | decrease | NF-κB | patients after CEA | P < 0.05 | decreased the expression | #7 |
melatonin | decrease | tumor necrosis factor-α | patients after CEA | P < 0.05 | decreased the expression | #8 |
melatonin | decrease | interleukin-6 (IL-6) | patients after CEA | P < 0.05 | decreased the expression | #9 |
melatonin | decrease | S100β | patients after CEA | P < 0.05 | decreased the expression | #10 |
melatonin | increase | Nrf2 | patients after CEA | P < 0.05 | increased the expression | #11 |
melatonin | increase | SOD | patients after CEA | P < 0.05 | increased the expression | #12 |
melatonin | increase | CAT | patients after CEA | P < 0.05 | increased the expression | #13 |
melatonin | increase | GPx | patients after CEA | P < 0.05 | increased the expression | #14 |
melatonin | decrease | brain I/R injury after CEA | - | - | could ameliorate | #15 |
Carotid endarterectomy (CEA) is the treatment of choice for carotid stenosis. Some patients develop ischemia and reperfusion (I/R) injury after CEA. This study was designed to investigate the neuroprotective effects of melatonin on I/R injury in both rats and humans. To this end, 36 male rats were evaluated, and a double-blind randomized controlled trial (RCT) including 60 patients was performed. A rat model of middle cerebral artery occlusion was used to mimic cerebral I/R. After 2 hour of occlusion and 24 hour of reperfusion, blood samples and brain tissues were harvested for further assessments. Compared with the vehicle treatment, melatonin decreased the expression of nuclear factor κ light-chain-enhancer of activated B cells (NF-κB) and S100 calcium-binding protein β (S100β) (P < 0.05) and markedly increased the expression of nuclear erythroid 2-related factor 2 (Nrf2), superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) (P < 0.05). The participants in the RCT took 6 mg/d melatonin orally from 3 days before surgery to 3 days after surgery. Blood samples were drawn at the following times: baseline; pre-anesthesia; carotid reconstruction completion; and 6, 24, and 72 hour after CEA. Compared with the oral placebo treatment, melatonin decreased the expression of NF-κB, tumor necrosis factor-α, interleukin-6 (IL-6), and S100β (P < 0.05) and increased the expression of Nrf2, SOD, CAT, and GPx (P < 0.05) in patients after CEA. Our findings suggested that melatonin could ameliorate brain I/R injury after CEA and that this outcome was essentially due to the antioxidant and anti-inflammatory effects of melatonin.